lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-15 and is reviewed periodically as new material appears.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20 °C or below | Desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity and identity |
| Common synonyms | Thymalfasin, T alpha 1 | Sequence identical to natural fragment |
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
ITUC stated their "total opposition" to all forms of corruption and "where corruption exists, workers are among its principal victims". ITUC stated that their decision to suspend Visentini "This in no way implies any presumption of guilt."
The first timepieces to be worn, made in 16th-century Europe, were transitional in size between clocks and watches. These 'clock-watches' were fastened to clothing or worn on a chain around the neck. They were heavy drum shaped brass cylinders several inches in diameter, engraved and ornamented. They had only an hour hand. The face was not covered with glass, but usually had a hinged brass cover, often decoratively pierced with grillwork so the time could be read without opening. The movement was made of iron or steel and held together with tapered pins and wedges, until screws began to be used after 1550. Many of the movements included striking or alarm mechanisms. The shape later evolved into a rounded form; these were later called Nuremberg eggs. Still later in the century there was a trend for unusually shaped watches, and clock-watches shaped like books, animals, fruit, stars, flowers, insects, crosses, and skulls (Death's head watches) were made. Styles changed in the 17th century and men began to wear watches in pockets instead of as pendants (the woman's watch remained a pendant into the 20th century). This is said to have occurred in 1675 when Charles II of England introduced waistcoats. To fit in pockets, their shape evolved into the typical pocket watch shape, rounded and flattened with no sharp edges. Glass was used to cover the face beginning around 1610. Watch fobs began to be used, the name originating from the German word fuppe, a small pocket. The watch was wound and also set by opening the back and fitting a key to a square arbor, and turning it.
Ronald E. Blaylock, Managing Partner of GenNx360 Capital Partners Albert Bourla, CEO of Pfizer Mortimer J. Buckley, former CEO of The Vanguard Group Sue Desmond-Hellmann, former CEO of The Bill and Melinda Gates Foundation Joseph J. Echevarria, former CEO of Deloitte LLP Scott Gottlieb, former Commissioner of the FDA Helen Hobbs, Professor at the University of Texas Southwestern Medical Center Susan Hockfield, 16th President of the Massachusetts Institute of Technology Dan Littman, professor of Molecular Immunology at New York University Shantanu Narayen, CEO of Adobe Suzanne Nora Johnson, former Vice Chairman of Goldman Sachs James Quincey, CEO of The Coca-Cola Company James C. Smith, former CEO of Thomson Reuters Cyrus Taraporevala, former president and CEO of State Street Global Advisor
Sources: en.wikipedia.org
Therapeutic touch (TT), or non-contact therapeutic touch (NCTT), also generically called healing touch, is a pseudoscientific energy therapy which practitioners claim promotes healing and reduces pain and anxiety. "Therapeutic Touch" is a registered trademark in Canada for the "[s]tructured and standardized healing practice performed by practitioners trained to be sensitive to the receiver's energy field that surrounds the body;...no touching is required." Practitioners of therapeutic touch state that by placing their hands on, or near, a patient, they are able to detect and manipulate what they say is the patient's energy field. One highly cited study, designed by the then-nine-year-old Emily Rosa and published in the Journal of the American Medical Association in 1998, found that practitioners of therapeutic touch could not detect the presence or absence of a hand placed a few inches above theirs when their vision was obstructed. Simon Singh and Edzard Ernst concluded in their 2008 book Trick or Treatment that "the energy field was probably nothing more than a figment in the imaginations of the healers". The American Cancer Society noted, "Available scientific evidence does not support any claims that TT can cure cancer or other diseases." A 2004 Cochrane review found no good evidence that it helped with wound healing, but the authors withdrew it in 2016 out of "serious concerns over the validity of included studies".
Pancreatic polypeptide cells (PP cells), or formerly as gamma cells (γ-cells), or F cells, are cells in the pancreatic islets (Islets of Langerhans) of the pancreas. Their main role is to help synthesize and regulate the release of pancreatic polypeptide (PP), after which they have been named. The pancreatic islets, where PP cells reside, was discovered in 1869 by a German pathological anatomist and scientist, Paul Langerhans. PP cells help to make up the pancreas but are smallest in proportion to the other cells previously stated. The proportions can vary based on which animals are being studied, but in humans, PP cells make up less than 2% of the pancreatic islet cell population.
The matter is automatically referred to the Independent Office for Police Conduct. 24 November – West Midlands Police is placed into special measures by Home Secretary James Cleverly after a review found it was not be effectively investigating or managing the risk to the public of sex offenders. 28 November – The Department for Education launches a consultation on how best to provide a minimum service level in schools in England during teaching strikes. 29 November – Natural England announces that England will be getting a new National Park. The Chilterns, The Cotswolds and Dorset could become new National Parks. Nottingham City Council declares itself effectively bankrupt, with a £23m overspend forecast for the 2023–24 financial year. Bigamist Jason Hayter of Frinton-on-Sea, Essex, is sentenced to eight weeks in prison suspended for 12 months and placed under night curfew for being married to two women simultaneously. 30 November – At least three police officers are injured during disorder ahead of a football match between Aston Villa and Legia Warsaw in Birmingham. Aston Villa confirms that no away fans were let into the stadium on the advice of police following the trouble.
The Edman degradation is a very important reaction for protein sequencing, because it allows the ordered amino acid composition of a protein to be discovered. Automated Edman sequencers are now in widespread use, and are able to sequence peptides up to approximately 50 amino acids long. A reaction scheme for sequencing a protein by the Edman degradation follows; some of the steps are elaborated on subsequently.
Sources: en.wikipedia.org
Lyophilized powder is normally kept at minus twenty degrees Celsius or below, in a sealed container, desiccated and away from light. Reconstituted solutions are less stable and are usually refrigerated and used quickly. Repeated temperature cycling should be avoided.
Mass spectrometry gives the molecular mass, which is compared with the calculated value. Reversed-phase liquid chromatography shows purity and the presence of related impurities. Peptide mapping can verify the amino acid sequence when a higher level of detail is needed.
It reports the tests the supplier performed, which may vary between laboratories and lots. Methods and acceptance criteria are not standardised across suppliers. Buyers often request the actual chromatograms and spectra rather than a summary statement.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.